Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the astir undervalued maturation stocks to buy, according to analysts. On March 12, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the assignment of David Ramsay arsenic the interim Chief Financial Officer, pending the assignment of a imperishable CFO.

Likoper/Shutterstock.com

Ramsay takes implicit arsenic CFO with implicit 30 years of acquisition successful strategical fiscal enactment crossed the biotechnology and beingness sciences sectors. He besides boasts of extended acquisition successful superior markets, firm finance, and capitalist relations. He antecedently served arsenic the company’s CFO from 2003 to 2009 and again from 2013 to 2015. During his tenure, the institution evolved from a backstage institution to a billion-dollar entity.

Earlier connected March 11, Halozyme Therapeutics outlined its maturation strategy astatine The Citizens Life Sciences Conference, projecting $1.7–$1.8 cardinal successful gross for the year, a 22%–30% increase. CEO Helen Torley emphasized the spot of ENHANZE drug‑delivery royalties, expected to scope $1.1–$1.2 billion, alongside contributions from products similar DARZALEX FASPRO and VYVGART HYTRULO. Despite ongoing patent litigation with Merck, Halozyme sees royalties unaffected and plans astatine slightest 3 caller deals successful 2026.

Financially, adjusted EBITDA is forecast astatine $1.1–$1.2 billion, supported by acquisitions specified arsenic Elektrofi and Surf Bio, which heighten its Hypercon exertion portfolio. With 7 ENHANZE products successful improvement and aggregate trials starting this year, Halozyme aims to person 40 drugs approved oregon successful improvement by 2028, positioning ENHANZE and Hypercon arsenic long‑term maturation drivers.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is simply a biotechnology institution focused connected processing and commercializing disruptive cause transportation technologies, chiefly utilizing its proprietary ENHANZE® technology. The exertion uses recombinant quality hyaluronidase (rHuPH20) to alteration rapid, high-volume subcutaneous injection of drugs typically administered intravenously.

While we admit the imaginable of HALO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Robinhood Stocks with High Potential and 10 Popular Penny Stocks connected Robinhood to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.